The mucosal immune system is uniquely adapted to elicit immune responses against pathogens but also to induce tolerogenic responses to harmless antigens. In mice, nasal application of ovalbumin (OVA) leads to suppression of both T h 1 and T h 2 responses. This tolerance can be transferred to naive mice by CD4 + T r cells from the spleen. Using the allotypic Ly5 system, we were able to demonstrate in vivo that T r cells not only suppress naive CD4 + T cells, but also induce them to differentiate into T r cells. The effector function of these mucosal T r cells is not restricted by cytokine polarization, since T r cells from T h 1-tolerant mice can suppress a T h 2 response and vice versa. Transfer of splenic CD4 + CD25 + and CD4 + CD25 ± T cell subsets from OVA-tolerized mice revealed that both subsets were equally able to suppress a delayed-type hypersensitivity response in acceptor mice. In contrast to the CD25 ± T cell subset, the CD25 + cells were not speci®c for the antigen used for tolerization. Together, these ®ndings demonstrate a role for CD4 + CD25 ± T r cells in mucosal tolerance, which suppresses CD4 + T cells in an antigen-speci®c fashion, irrespective of initial T h 1/T h 2 skewing of the immune response. This offers a major advantage in the manipulation of mucosal tolerance for the treatment of highly cytokine-polarized disorders such as asthma and autoimmune diseases.
Introduction
A characteristic feature of the mucosal immune system is its ability to tailor the immune response to the type of antigen that is encountered. As a result, pathogens generally elicit an active mucosal response, whereas innocuous antigens are generally tolerated. Mucosal tolerance, characterized by speci®c immunologic unresponsiveness to subsequent antigenic challenge, may be achieved by either the induction of anergy, deletion of responsive cells or active cellular regulation via T r cells (1, 2) . Recent observations clearly demonstrate that multiple types of T r cells can be distinguished by lineage, expression of surface markers and cytokine production (1,3±5) . A large number of recent studies have focused on naturally occurring CD4 + CD25 + T r cells, which are derived from the thymus, and, once activated via the TCR, can suppress systemic immune responses against self and foreign antigens. This was demonstrated by depletion of this T r cell population in mice, which induces severe and fatal autoimmunity, characterized by wasting disease and autoimmune in¯ammation in multiple organs (6) . Transfer of these CD4 + CD25 + T r cells to lymphopenic recipients prevents the development of autoimmunity (6±9). The mechanism of this suppression is dependent on cell±cell interactions, possibly mediated via cytotoxic T lymphocyte-associated antigen (CTLA)-4, and secretion of immunoregulatory cytokines such as IL-10 and transforming growth factor (TGF)-b (8, 10, 11) .
In addition to these thymic-derived T r cells, another subset of T r cells is generated in the periphery in response to administration of soluble antigen via the mucosa (1) . Recently, we observed that intrinsic characteristics of the nasal draining lymph nodes are critically important for the induction of tolerance via the nasal mucosa. A series of transplantation experiments revealed not only that the presence of cervical lymph nodes was necessary for nasal tolerance induction, but also that this function could not be assumed by peripheral lymph nodes when transplanted to this site (12) . After nasal or oral tolerance induction, the T r cells that can be isolated from the spleen and that are able to transfer tolerance, are CD4 + T cells (mucosal T r cells), but not CD8 + T cells (13, 14) . More detailed knowledge of the phenotype of these mucosal T r cells is lacking.
It is unclear what fate the transferred mucosal T r cells undergo in the naive recipient. Do the transferred T r cells expand by proliferation, establishing an exponentially increasing cohort of cells that suppress a subsequent sensitization and challenge? Or do these mucosal T r cells transfer the regulatory capacity to a naive CD4 + T cell of the recipient that subsequently suppresses sensitization and challenge?
Furthermore, little is known about the plasticity of the T r cells that are generated after mucosal tolerance induction. During polarization of naive T cells into effector T h 1 and T h 2 cells, their plasticity is lost. As a result, after three to four cell divisions, T h 1 and T h 2 cells are incapable of re-expressing alternative cytokines when re-stimulated under opposing conditions (15) . Previously, we have established that application of ovalbumin (OVA) via the mucosa is effective in the suppression of highly polarized T h 1 and T h 2 immune responses. It is unclear whether, after adoptive transfer and subsequent T h 1 or T h 2 sensitization and challenge, the mucosal T r cells are in¯u-enced by the polarized environment in the host. Do the T r cells retain their suppressive capacity in the recipient or do these cells acquire an irreversible differentiation analogous to T h 1 and T h 2 cells?
In this study we have addressed three questions on the fate, plasticity and identity of mucosal T r cells that are generated after nasal tolerance induction. We show that T r cells, induced by nasal OVA application, mediate tolerance by passing the tolerizing capacities on to naive CD4 + T cells. Surprisingly, these mucosal T r cells do not loose plasticity during their differentiation from naive CD4 + T cells, as demonstrated by the capacity to suppress naive T cells irrespective of initial or ongoing cytokine polarization of the immune response. Finally, we show that T r cells reside in both CD25 + and CD25 ± subpopulations; however, only the CD25 ± T r cells display antigen speci®city.
Methods

Mice
Female BALB/c mice (8±12 weeks old) were obtained from Charles River (Sulzfeld, Germany) and kept under standard animal housing conditions. The congenic C57BL/6-Ly5.1 and C57BL/6-Ly5.2 mice were bred at our own facilities, and used at 8±12 weeks of age. The C57BL/6-Ly5.1 and C57BL/6-Ly5.2 mice express different allotypes of the CD45 (Ly5) antigen, which can be distinguished with mAb. Mice used in experiments were sex and age matched. All experiments were approved by The Animal Experiments Committee of the VUMC.
Induction of tolerance and subsequent antigen sensitization for delayed-type hypersensitivity (DTH) or allergic response
To induce tolerance, mice received 10 ml saline containing 100 mg OVA (type VII; Sigma, St Louis, MO) intranasally on each of 3 consecutive days. Control mice received 10 ml saline intranasally. Previously, we have described two models resulting in opposite cytokine-skewing, denoted as T h 1 (lacking IgE) and T h 2 [lacking IFN-g (13) ].
Mice were sensitized for a T h 1 response as previously described (13) . In short, 25 ml incomplete Freund's adjuvant (IFA; Difco, Detroit, MI) mixed with 25 ml saline containing 100 mg OVA was injected s.c. in the tail base 1 day after the last intranasal OVA or saline administration. Five days later, a challenge was given by injecting 20 ml saline, which contained 10 mg OVA, in the auricles of both ears. Directly before challenge, the initial thickness of the ear was determined with an engineer's micrometer (Mitutoyo, Tokyo, Japan). DTH responses were expressed as the mean increase in ear thickness of both ears 24 h post-challenge, following subtraction of the mean ear thickness before challenge. In some experiments, mice were sensitized and challenged for a T h 1 response using hen egg lysozyme (HEL; Sigma). The same amounts of HEL were used for sensitization and challenge as were used for sensitization and challenge with OVA. In all experiments the ear thickness was measured in a blinded fashion.
Sensitization for a T h 2 response was performed as described previously (14) . Brie¯y, on days 1 and 14 after the last intranasal OVA treatment, mice received an i.p. injection of 2 mg OVA dissolved in 100 ml saline mixed with 100 ml aluminum hydroxide rehydragel (AlOH; Reheis Chemical, Berkely Heights, NJ). Four days after the second injection, mice were challenged intragastrically with 200 ml saline containing 1 mg OVA. As a parameter for the T h 2 response, IgE levels were measured. Blood was collected via a small incision in the tail vein at t = ±2, 0, 2, 4 and 6 days with regard to the intragastric challenge, and stored as serum at ±80°C until IgE levels were measured.
Measurement of serum IgE by ELISA
Both total and OVA-speci®c IgE serum levels were determined by using a modi®ed capture ELISA as described elsewhere (16 Experiments with C57BL/6-Ly5.1 and C57BL/6-Ly5.2 mice C57BL/6-Ly5.1 + mice were tolerized and sensitized for a DTH response as described. Seven days after challenge, spleens from tolerant and naive control mice were collected. Singlecell suspensions were obtained by mincing the spleens and straining them through 100-mm gauze. Erythrocytes were depleted from this cell suspension by incubation in a lysis buffer (150 mM NH 4 Cl and 1 mM NaHCO 3 , pH 7.4) for 5 min on ice. For partial puri®cation of CD4 + T cells, the spleen cells were incubated for 30 min on ice with a B cell-speci®c rat mAb [clone 6B2, anti-B220; af®nity puri®ed from culture supernatant of hybridoma cells with Protein G±Sepharose (Pharmacia, Uppsala, Sweden)]. Next, the cells were washed and resuspended in HBSS (Biowhittaker, Verviers, Belgium) supplemented with 1% heat-inactivated FCS. Subsequently, sheep anti-rat IgG Dynabeads (Dynal, Oslo, Norway) were added in a 2:1 bead:cell ratio. After 30 min incubation on a rotator at 4°C, positively stained B cells were depleted using a magnetic particle concentrator (MPC; Dynal). The remaining cell population contained between 50 and 60% CD4 + T cells, as determined by¯ow cytometry (FACStar; Becton Dickinson). Previously, we have shown that the contaminating CD8 + T cells do not transfer tolerance (14) . The enriched CD4 + T cells were washed, resuspended in saline and 2±5 Q 10 6 cells were transferred to naive C57BL/6-Ly5.2 + acceptor mice by i.v. injection via the lateral tail vein. Upon transfer, the acceptor mice were sensitized for a T h 1 response. Seven days after challenge, the spleens were collected from these C57BL/6-Ly5.2 + tolerant mice and partially puri®ed CD4 + T cells were isolated from single-cell suspensions. To determine whether the CD4 + Ly5.2 + T cells had also become suppressive, highly puri®ed CD4 + T cells were used. These were prepared by incubation of the enriched CD4 + T cell population with biotinylated anti-Ly5.1 antibody (clone A20; af®nity puri®ed from culture supernatant of hybridoma cells with Protein G±Sepharose and biotinylated according to the manufacturer's instruction), FITC-conjugated anti-Ly5.2 antibody (clone AL-1; af®nity puri®ed from culture supernatant of hybridoma cells with Protein G±Sepharose and labeled with FITC according to the manufacturer's instructions) and phycoerythrin (PE)-conjugated anti-CD4 antibody (GK1.5; PharMingen) for 30 min on ice. After washing, CD4 + Ly5.2 + Ly5.1 ± T cells were sorted by¯ow cytometry. The cells were washed, resuspended in saline and 1 Q 10 6 CD4 + T cells were transferred to naive acceptor mice by i.v. injection via the lateral tail vein.
Transfer experiments with BALB/c mice
For transfer of tolerance, donor BALB/c mice were tolerized and sensitized for a T h 1 response or a T h 2 response as described. Spleens of T h 1-tolerant mice were collected and pooled 7 days post-challenge, whereas spleens of T h 2-tolerant animals were collected at 4 days post-challenge. As a control, spleens from naive BALB/c mice were taken and partially puri®ed CD4 + T cells were isolated from single-cell suspensions as described above.
For transfer of puri®ed CD4 + CD25 + T cells and CD4 + CD25 ± T cells, the enriched CD4 + T cells were stained with FITCconjugated anti-CD4 antibody (clone GK1.5, af®nity puri®ed from culture supernatant of hybridoma cells with Protein G±Sepharose and FITC-labeled according to the manufacturer's instructions), PE-conjugated anti-CD25 antibody (clone PC61, anti-IL2Ra; PharMingen) and biotinylated anti-MHC class II antibody (clone M5/114, af®nity puri®ed from culture supernatant of hybridoma cells with Protein G±Sepharose) for 30 min on ice. After washing, CD4 + CD25 + and CD4 + CD25 ± T cells were sorted (FACSVantage; Becton Dickinson). The CD4 + CD25 + T cell population was approximately 90% pure (the remaining 10% consisted of 6% CD4 ± CD25 ± cells and 4% CD4 + CD25 ± cells) and the purity of the CD4 + CD25 ± cell population was~98% as determined by re-analysis. After washing, the cells were resuspended in saline and 10 5 cells were transferred to naive acceptor mice by i.v. injection via the lateral tail vein.
When CD4 + CD25 + T cells and CD4 + CD25 ± T cells were puri®ed using MACS microbeads, the enriched CD4 + T cells were incubated with biotinylated anti-CD25 antibody (clone PC61; PharMingen) for 15 min on ice, followed by anti-biotin immunomagnetic beads (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 min at 4°C. Magnetic separation was performed with an MS column according to the suggested protocol. The CD4 + CD25 + T cell population was~80% pure (the remaining 20% consisted of 14% CD4 ± CD25 ± cells and 6% CD4 + CD25 ± cells) and the purity of the CD4 + CD25 ± cell population was~86% (the remaining 14% consisted mainly of CD4 ± CD25 ± cells) as determined by re-analysis. After washing, the cells were resuspended in saline and 10 5 cells were transferred to naive acceptor mice by i.v. injection via the lateral tail vein.
To determine whether dendritic cells (DC) were capable of transferring tolerance, puri®ed splenic DC were used. DC were isolated from a suspension of spleen cells using antiCD11c immunomagnetic beads (MACS) according to the manufacturer's instructions. This enriched DC population was then incubated with FITC-conjugated anti-MHC class II antibody (clone M5/114) and PE-conjugated anti-CD11c antibody (clone HL3; PharMingen) for 30 min on ice. Further puri®ed CD11c + MHC class II + DC were obtained by¯ow sorting. After washing, cells were resuspended in saline and the numbers indicated were transferred to naive acceptor mice by i.v. injection via the lateral tail vein.
Proliferation assays
Lymph nodes were isolated from tolerant and non-tolerant mice 1 week after ear challenge. Single-cell suspensions were cultured with 0.5 mg/ml OVA in U-bottomed 96-well plates at 5 Q 10 6 cells/ml in DMEM (Gibco, Life Technologies, Breda, The Netherlands) supplemented with 10% heat-inactivated FCS (Biowhittaker), 50 U/ml sodium penicillin G (Biowhittaker), 50 mg/ml streptomycin (Biowhittaker), 2 mM L-glutamine (Biowhittaker) and 50 mM b-mercaptoethanol (Merck, 
Statistics
For ear swelling responses, the mean increase in ear thickness of both ears was determined for each mouse per group. For T h 2 responses, data are expressed as mean IgE levels T SD per group. Groups consist of seven mice, unless otherwise indicated. Groups were compared using an ANOVA followed by the Tukey±Kramer multiple comparisons test for ear swelling responses. For serum IgE levels, a MANOVA was used. For proliferation assays, data are expressed as mean values of triplicates. Groups were compared to the control group using an unpaired t-test. P < 0.05 was considered signi®cant.
Results
Fate of T r cells after transfer to a naive recipient
Application of OVA via the nasal mucosa leads to suppression of a subsequent DTH response, consisting of a sensitization with OVA in the tail base and a challenge in the ears. This tolerance can be transferred to naive recipients by i.v. injection of puri®ed CD4 + T r cells from spleens of tolerant mice. It is unclear what the fate is of these CD4 + T r cells in the naive recipients. We hypothesized that the transferred CD4 + T r cells either expand by proliferation to develop an exponentially growing cohort of suppressor cells that suppress sensitization and challenge or, on the other hand, that these CD4 + T r cells, in the presence or absence of an antigen-presenting cell (APC), transfer their regulatory capacity to the naive CD4 + T cells in the recipient.
To follow the fate of the tolerizing T r cells, mice with an allelic difference in Ly5 (CD45) were used which enabled us to discriminate between donor and recipient cells. Donor C57BL/ 6-Ly5.1 mice received an intranasal OVA instillation on 3 consecutive days. One day after the last nasal intranasal OVA administration, mice were sensitized for a DTH response by an injection of OVA/IFA s.c. Five days later, mice were challenged by an injection of OVA in the auricles of both ears. Nasal OVA treatment led to tolerance as only marginal ear swelling was measured (mean increase in ear thickness was 5.25 T 0.54 compared to 10.58 T 2.75 x 10 ±2 mm in control mice treated nasally with saline). From these tolerant C57BL/6-Ly5.1 mice splenic CD4 + T cells were puri®ed and transferred into naive C57BL/6-Ly5.2 recipient mice (transfer I, Fig. 1A) . These C57BL/6-Ly5.2 recipient mice were then sensitized and challenged with OVA to con®rm that they had become tolerant after this cell transfer (mean increase in ear thickness was 5.43 T 0.73 versus control 9.83 T 1.66 x 10 ±2 mm). To rule out the possibility that a non-responsive T cell population was induced, simply due to the regimen of sensitization and challenge, splenic CD4 + T cells from mice that had received saline intranasally were adoptively transferred to naive recipients. Transfer of CD4 + T cells from these OVA-primed mice did not inhibit the DTH response in the recipient mice (mean increase in ear thickness was 10.88 T 1.62 versus control Fig. 1 . Fate of T r cells after transfer to a naive recipient. (A) C57BL/ 6-Ly5.1 + mice were tolerized by intranasal instillation of 100 mg OVA on each of 3 consecutive days. One day later, mice were sensitized for a T h 1 response by a s.c. injection of 100 mg OVA in IFA, followed 5 days later by an injection of 10 mg OVA in each ear. Seven days after ear challenge CD4 + splenic T cells from tolerant C57BL/6-Ly5.1 + mice were isolated and 5 Q 10 6 cells were adoptively transferred to naive C57BL/6-Ly5.2 + mice by i.v. injection in the tail. Upon transfer, the C57BL/6-Ly5.2 + acceptor mice were sensitized and challenged for a T h 1 response with OVA as described for the donor mice. Seven days after challenge, spleens were collected from the tolerant mice, and both CD4 + -enriched T cells (containing Ly5.1 + as well as Ly5.2 + T cells, grey squares) and highly puri®ed CD4 + Ly5.2 + Ly5.1 ± T cells (open circles) were isolated and 1 Q 10 6 cells were adoptively transferred to each of seven naive acceptor mice. (B) The acceptor mice of CD4 + -enriched T cells, the recipients of highly puri®ed CD4 + Ly5.2 + T cells and control mice which received 1 Q 10 6 naive splenic CD4 + T cells (black circles) were sensitized for a T h 1 response as previously described. Each point represents the mean increase in ear thickness of both ears per mouse 24 h after challenge of the ®nal group of Ly5.1 + acceptor mice. Bars indicate the mean of each group. An asterisk indicates a signi®cant difference between acceptors of tolerant cells and control mice (P < 0.001). One representative experiment is shown. Similar results were also obtained in one further experiment (n = 15 per group).
11.81 T 2.49 x 10 ±2 mm), indicating that these cells remain responsive to antigenic stimulation. This adoptive transfer system was then pursued further to determine whether the original donor Ly5.1 + CD4 + T r cells were responsible for the suppression in the recipient mice or whether these T r cells had transferred their regulatory capacity on to the CD4 + T cells of the C57BL/6-Ly5.2 recipient. Therefore, splenic cells of the tolerant recipients were stained for donor (Ly5.1) and recipient (Ly5.2) allotypes, and separated into a puri®ed population of Ly5.2 + Ly5.1 ± CD4 + T cells (recipient), and a population containing both Ly5.1 + (donor) and Ly5.2 + CD4 + (recipient) T cells. The Ly5.2 + CD4 + T cell population was~97% pure as determined by¯ow cytometric re-analysis. The contaminating 3% were Ly5.2 + CD4 ± cells, but contained no Ly5.1 donor cells. Subsequently, 1 Q 10 6 cells of each population were transferred to naive acceptor mice in a second series of transfers (transfer II, Fig. 1A) . As a control, 1 Q 10 6 splenic CD4 + T cells from naive, non-OVA-exposed mice were also transferred to naive recipients.
As shown in Fig. 1(B) , the Ly5.2 + CD4 + T cells of the recipient of transfer I are able to suppress the DTH response in naive recipients (group A), indicating that they have become T r cells. Recipients of both Ly5.1 + and Ly5.2 + CD4 + T cells (group B) were also tolerant, as ear swelling responses were similar to those in recipients of Ly5.2 + CD4 + T cells, but signi®cantly different from recipients of naive CD4 + T cells (group C).
Moreover, it should be noted that at the time of isolation of CD4 + cells for transfer II, the spleens of the C57BL/6-Ly5.2 + mice contained only a minor fraction of CD4 + T cells (<0.5% of total CD4 + T cells) of the original donor Ly5.1 allotype.
Recent studies have shown that APC can mediate T cell suppression, either upon cross talk with`anergic' T cells, or via the secretion of IL-10 and/or TGF-b (17, 18) . To exclude the possibility that the results obtained from both T cell transfers I and II were due to contaminating DC, adoptive transfers were performed with puri®ed splenic DC from OVA-tolerized mice. In our hands, transfer of 5 Q 10 4 DC, a number which is at least 5-fold excess of the possibly contaminating DC in both transferred T cell populations, did not inhibit the DTH response in recipient mice (mean increase in ear thickness was 8.45 T 1.15 versus control 9.56 T 1.15 Q 10 ±2 mm).
Together, these results clearly demonstrate that T r cells, when transferred to naive recipients, induce the CD4 + T cells of the recipient to differentiate into T r cells.
Transferred CD4 + T r cells retain their suppressive capacity in a polarized environment
In the experiments described above, mice were challenged to develop a DTH response, a type of stimulus that is biased towards inducing T h 1 cells. Previously, we have shown in an allergy model that nasal OVA application can effectively tolerize polarized T h 2 responses, as measured by the suppressive effect on both total and OVA-speci®c IgE production (16) . Since upon differentiation T h 1 and T h 2 cells undergo irreversible lineage commitment, we questioned whether after de®ned sensitization and challenge T r cells would also lose their plasticity. To test this, we assessed whether T r cells from a T h 1-biased animal would be able to suppress the sensitization of both T h 1 and T h 2 responses, and whether this also applied to T r cells from a T h 2-biased animal.
To induce tolerance, mice received a nasal OVA application on each of 3 consecutive days. Thereafter, mice were divided in two groups. One group was sensitized for a DTH response by an injection of OVA/IFA s.c. (T h 1-type response). Five days later, mice were challenged by an injection of OVA in the auricles of both ears. It was con®rmed that nasal OVA-treated mice were tolerant (mean increase in ear thickness was 4.03 T 0.66 Q 10 ±2 mm), as ear swelling responses were reduced in comparison to saline-treated mice, which displayed signi®-cantly enhanced ear swelling responses (mean increase in ear thickness was 9.38 T 1.27 Q 10 ±2 mm). The other group was sensitized for an allergic response by two i.p. injections of OVA in AlOH with a 2-week interval (T h 2-type response). Four days after the last i.p. injection, mice were challenged for IgE by an intragastric injection of OVA. In the sera from mice treated with OVA intranasally signi®cantly lower IgE levels were detected (2687.99 T 753.64 ng/ml total IgE) than in sera from saline treated mice (8805.25 T 588.32 ng/ml total IgE, on day 4 after challenge), indicating tolerance. From the spleens from T h 1-tolerant and T h 2-tolerant mice, CD4 + T r cells were puri®ed and transferred into naive recipients (T h 1 and T h 2 acceptors respectively). Control mice received naive splenic CD4 + T cells. Upon transfer, T h 1 acceptors, T h 2 acceptors and control mice were divided in two groups; half of the mice were sensitized for a T h 1 response, whereas the other half of the mice were sensitized for a T h 2 response. As depicted in Fig. 2 , Fig. 2 . CD4 + T r cells derived from a strongly T h 2-biased donor retain their plasticity to suppress a T h 1 response. BALB/c mice were treated intranasally with 100 mg OVA on each of 3 consecutive days. One day later, half of the mice were sensitized for a T h 1 response by a s.c. injection of 100 mg OVA in IFA, followed 5 days later by an injection of 10 mg OVA in both ears. The second half of the group was sensitized for a T h 2 response by two i.p. injections of 2 mg OVA in AlOH with a 2-week interval, followed by an intragastric injection of 1 mg OVA 4 days after the second i. intimm.oxfordjournals.org the acceptor mice that were sensitized for a T h 1 response showed a similar reduction in DTH response irrespective whether the transferred CD4 + T r cells were derived from T h 1-or T h 2-tolerant animals.
Similar results were found when acceptor mice were sensitized for a T h 2 response (Fig. 3A and B) . Where control mice developed substantial (total and anti-OVA) IgE levels, strongly reduced IgE levels were seen in animals that had received either T h 1 or T h 2 T r cells prior to sensitization and challenge ( Fig. 3A and B) .
In conclusion, these results clearly show that CD4 + T r cells derived from a strongly T h 2-biased donor retain their capacity to suppress a T h 1 response and vice versa.
Identi®cation of subsets of mucosal CD4 + T r cells
Until now, it has been unclear whether the regulatory activity of mucosal T r cells is limited to a speci®c subset of CD4 + splenocytes. Flow cytometric analysis of CD4 + T r splenocytes and control CD4 + splenocytes from a non-tolerized donor did not yield any signi®cant phenotypic differences. Since the detection limit may be too high to distinguish a discriminating marker of a T r subset and in view of the vast amount of data demonstrating a role for CD4 + CD25 + T cells in immune regulation (5), we determined whether the mucosal CD4 + T r cells are CD25 + or CD25 ± . Therefore, mice were tolerized by a nasal OVA instillation on 3 consecutive days. These mice were then sensitized for a T h 1 response by an injection of OVA/IFA s.c. and challenged by an injection of OVA in the auricles of both ears to con®rm tolerance (mean increase in ear thickness was 4.7 T 0.48 versus control 9.56 T 0.72 Q 10 ±2 mm).
One week after challenge, splenic CD4 + T r cells from the T h 1-tolerant mice were sorted into CD25 + (90% pure) and CD25 ± (98% pure) fractions, and subsequently transferred to naive acceptor mice. As a control, splenic CD4 + T cells were from naive, non-OVA-exposed mice were also transferred to naive recipients. The acceptor mice were then sensitized and challenged for a T h 1 response with either OVA or an unrelated antigen HEL. It was observed that the CD4 + CD25 + T cells from tolerant mice were able to suppress both the OVA-and HELspeci®c DTH responses, whereas the CD4 + T cells from nontolerized donors failed to induce tolerance to either antigen in the recipient (Fig. 4) . In contrast to the CD4 + CD25 + subset, the CD4 + CD25 ± T cells only suppressed the DTH response against OVA, but not the DTH response against HEL. This demonstrates that suppression by the CD4 + CD25 ± population requires the antigen used for tolerization, whereas suppression by the CD4 + CD25 + T cells is not speci®c for the applied antigen.
To con®rm the in vivo data shown in Fig. 4 , facial lymph node cells of the recipient mice were isolated after sensitization and challenge with either OVA or HEL, and proliferative responses were measured in vitro. As shown in Fig. 5 , T cell proliferative responses to OVA were suppressed in cultures of CD4 + CD25 + T cell recipients as well as CD4 + CD25 ± T cell recipients when Fig. 3 . CD4 + T r cells derived from a strongly T h 1-biased donor retain their plasticity to suppress a T h 2 response. BALB/c mice were treated intranasally with 100 mg OVA on each of 3 consecutive days. One day later half of the mice were sensitized for a T h 1 response, whereas the second half were sensitized for a T h 2 response, as described in the legend to Fig. 2 . CD4 + T cells (5 Q 10 6 ) from either T h 1-tolerant or T h 2-tolerant mice were transferred to naive mice (T h 1 acceptors and T h 2 acceptors respectively). Control mice received 5 Q 10 6 naive splenic CD4 + T cells. Upon transfer, the T h 1 acceptors, T h 2 acceptors and control mice were sensitized for a T h 2 response. The mean level of total (A) and OVA-speci®c (B) IgE of seven mice is shown. An asterisk indicates a signi®cant difference between acceptors of T h 1-or T h 2-tolerant cells and control mice (P < 0.0003). Similar results were obtained in one further experiment. Fig. 4 . Suppression by the CD4 + CD25 ± T cell subset is speci®c for the antigen used for intranasal tolerization, whereas that of CD4 + CD25 + T cells is not. Mice were treated intranasally with 100 mg OVA on each of 3 consecutive days followed by sensitization for a DTH response as described in the legend to Fig. 1 . One week later, CD4 + CD25 + T cells and CD4 + CD25 ± T cells were isolated from the spleens of these tolerant mice, and adoptively transferred to groups containing ®ve naive acceptor mice. Subsequently, the recipients of 10 5 highly puri®ed CD4 + CD25 + or CD4 + CD25 ± T cells were sensitized for a DTH response, as described in the legend to compared to cells from naive T cell recipients. In contrast, proliferative responses to HEL were only suppressed in cultures of CD4 + CD25 + T cell recipients, whereas the responses of CD4 + CD25 ± T cell recipients and naive T cell recipients were comparable. Thus, these data mirror and con®rm the results obtained in vivo.
Since the CD25 + T r cells do not show antigen speci®city and in this respect resemble the thymic-derived CD25 + T r cells, we wondered whether the latter contributed to the observed suppression. Therefore, adoptive transfers were performed with puri®ed CD4 + CD25 + T cells and CD4 + CD25 ± T cells from tolerized, primed and naive mice. Consequently, mice that had received either OVA or saline intranasally on 3 consecutive days were sensitized for a T h 1 response by an injection of OVA/IFA s.c. and challenged by an injection of OVA in the auricles of both ears. It was con®rmed that nasal OVA-treated mice were tolerant (mean increase in ear thickness was 3.95 T 1.09 Q 10 ±2 mm), as ear swelling responses were reduced in comparison to saline-treated mice, which displayed enhanced ear swelling responses (mean increase in ear thickness was 8.95 T 1.24 Q 10 ±2 mm). One week after challenge, splenic CD4 + T cells from tolerant, non-tolerant (primed) and naive mice were puri®ed into CD25 + (80% pure) and CD25 ± (87% pure) fractions, and subsequently transferred to naive acceptor mice. The acceptor mice were then sensitized and challenged for a T h 1 response with OVA. As a control, mice that had not received T cells were sensitized and challenged for a T h 1 response with OVA. As depicted in Fig. 6 , DTH responses were signi®cantly suppressed in mice that had received CD4 + CD25 + and CD4 + CD25 ± T cells from tolerized mice, whereas no suppression was observed in those that received the same subsets from naive or from primed mice as ear swelling was as pronounced as seen in control mice.
In conclusion, the results clearly demonstrate that mucosal T r cells are present in both CD4 + CD25 + and CD4 + CD25 ± subsets. Moreover, only in the CD4 + CD25 ± subset, but not in the CD4 + CD25 + T cell subset, were T r cells found that were speci®c for the antigen to which tolerance was generated.
Discussion
In this report we have studied fate, plasticity and the identity of mucosal T r cells in a murine model of adoptive transfer. 5 . Proliferative OVA-tolerized T cell responses to HEL are only suppressed in lymph node cultures of CD4 + CD25 ± T cell acceptors. Mice were treated intranasally with 100 mg OVA on each of 3 consecutive days followed by sensitization for a DTH response as described in the legend to Fig. 1 . One week later, CD4 + CD25 + T cells and CD4 + CD25 ± T cells were isolated from the spleens of tolerant mice, and adoptively transferred to groups of seven naive acceptor mice. Subsequently, the recipients of 10 5 highly puri®ed CD4 + CD25 + or CD4 + CD25 ± T cells were sensitized for a T h 1 response either with OVA or the unrelated antigen HEL. Control mice received 10 5 naive splenic CD4 + T cells. Seven days after ear challenge, facial lymph nodes were collected and re-stimulated in vitro. Four days later cultures were pulsed with [ 3 H]thymidine and incorporation was determined. An asterisk indicates a signi®cant difference between acceptors from T r cells and controls (P < 0.05). Fig. 6 . The CD4 + CD25 + T cell subset from OVA-tolerized mice is induced by mucosal OVA application. Mice were treated intranasally either with 100 mg OVA or saline on each of 3 consecutive days followed by sensitization for a DTH response as described in the legend to Fig. 1 . One week later, CD4 + CD25 + T cells and CD4 + CD25 ± T cells were puri®ed from the spleens of tolerant, primed and naive mice by MACS microbeads, and adoptively transferred to groups of six naive acceptor mice. Subsequently, the recipients of 10 5 highly puri®ed CD4 + CD25 + or CD4 + CD25 ± T cells were sensitized for a T h 1 response as described in the legend to We report that in mice, application of OVA via the nasal mucosa induces CD4 + T r cells in the spleen that mediate tolerance by transferring their regulatory capacity to naive T cells in vivo. These T r cells retain their plasticity in polarized microenvironments, as demonstrated by the ®nding that mucosal T r cells recovered from a T h 2-biased mouse are capable of suppressing both T h 1 and T h 2 responses, and with equal potency as mucosal T r cells recovered from a T h 1-biased mouse. Moreover, both CD4 + CD25 + and CD4 + CD25 ± subsets exerted regulatory activity. However, only the CD4 + CD25 ± suppressed responses speci®c for the antigen used for tolerization.
Our observation that mucosal T r cells transfer their regulatory activity to naive T cells in a naive recipient resembles properties of T r cells that were described in tissue transplantation studies (19) . In these studies, tolerance induced to skin grafts using non-depleting anti-T cell mAb was reported as being`infectious'. It is unclear why mucosal T r cells transfer their function instead of expanding exponentially. However, the characteristic of poor division has been observed for many cells with suppressor activity. For example, naturally existing CD25 + T r have been reported to be anergic to stimulation via the TCR, but to proliferate and even lose their tolerogenic capacity upon addition of exogenous IL-2 (20, 21) .
The cellular interactions that regulate the transfer of the suppressive activity from a T r cell to a naive T cell may comprise a sequence of events. Initially, after i.v. transfer and subsequent sensitization of the acceptor mouse with OVA, the T r cell may encounter an APC that presents OVA in the vicinity of a naive CD4 + T cell. Upon recognition of antigen in the context of an APC the T r cell will be activated and may regulate the naive T cell via multiple pathways. Regulation may involve direct signaling, e.g. via Notch, that has previously been suggested to block the differentiation of precursor T cells into both T h 1 and T h 2 cells (22) . Furthermore, since T cells also express Notch ligands, the suppressed T cells may signal to adjacent naive T cells to further spread the block in differentiation and may thus render cells competent for subsequent regulation steps (23) . Other regulatory mechanisms may be provided by the secretion of anti-in¯ammatory cytokines, such as IL-10 and TGF-b by either the T r cell or the APC (10, 11, 18, 24) . However, it has been shown that IL-10 does not play a role in nasal tolerance, since administration of anti-IL-10 mAb either during the induction or during sensitization does not restore DTH responses in nasally tolerized mice (13) . A recent in vitro study using human naturally existing CD25 + CD4 + T r cells elegantly showed that these T r cells need cell±cell interaction for suppression and transfer of tolerogenic potencies, whereas the induced secondary CD4 + suppressor T cells do not (25) . Instead, these cells inhibit via soluble mediators like TGF-b. Whether these mechanisms are also operating in our in vivo model is unclear. However, the CD25 ± T r subset may suppress differently than the CD25 + T r population, since we observed that the former is antigen speci®c, whereas the latter is not. In addition, down-regulation of the response may involve surface molecules such as CTLA-4 and PD-1 (8, 26) . The contribution of each of these pathways is the subject of current investigation. Surprisingly, the microenvironment in which the mucosal T r cells spread their tolerance to naive cells does not affect the plasticity of the response. The potency to suppress T h 1 and T h 2 responses did not differ between T r cells derived from a T h 1-biased mouse and a T h 2-biased mouse. Although these data suggest that T r cells retain their plasticity, it cannot be excluded that within the T r population`T h 1-or T h 2-biased' T r cells exist. This broad down-regulatory activity is very encouraging when we consider the potential use of mucosal T r cell induction for the treatment of immunological disorders that are characterized by highly polarized cytokine pro®les. Furthermore, since previous and ongoing cytokine responses do not alter the suppressive capacity of the T r cell, this observation indirectly underlines the tight regulation with which the T r cell exerts its suppressive function.
To unravel the intrinsic properties of mucosal T r cells, it is of key importance to determine their phenotype and to assess their relationship with other types of T r cells that have been described. In this study, we demonstrate that both splenic CD4 + CD25 + and CD4 + CD25 ± T cell subsets isolated from mice that were tolerized intranasally with OVA were equally capable of suppressing a systemic challenge to OVA. However, only the CD4 + CD25 ± T cell subset shows antigen speci®city.
Our observation that the CD4 + CD25 + T cell population suppresses responses to the unrelated antigen HEL is in accordance with the current literature and suggests that these cells may represent a peripheral version of the thymus-derived CD4 + CD25 + T r cells (6, 27) . However, if the CD4 + CD25 + T r subset would largely be constituted of thymus-derived T r cells, it could be expected that the CD4 + CD25 + subset from naive mice would also suppress the DTH response. Since the latter subset failed to induce tolerance in the recipient mice at the same ratios, it may imply that the CD4 + CD25 + T r cells from nasally tolerized mice are indeed mucosally induced, as has been suggested for low-dose oral tolerance induction (28, 29) . The absence of suppressive activity by the CD25 + T r subset from naive mice could be explained by the fact that it may depend on the ratio of suppressor and effector cells.
We are the ®rst to report that CD4 + CD25 ± T cells induced by nasal antigen application suppress systemic challenge in an antigen-speci®c manner. It is questioned where these T cells are generated. We have previously shown that the cervical lymph nodes are essential for the induction of nasal tolerance (12) and therefore we hypothesize that the application of OVA via the nasal mucosa causes naive T cells to differentiate into CD4 + CD25 ± T r cells under the in¯uence of a speci®c microenvironment present only in these lymph nodes. Moreover, once mucosal T r cells have been generated, other naive CD4 + T cells may acquire their suppressive capacity in non-mucosal tissue via the mechanism of`infectious' tolerance. Whether the CD4 + CD25 ± T cells are related to the recently described naturally existing CD4 + CD25 + T r subset is unclear. To our knowledge, there is no evidence that the thymus exports any CD4 + T cells pre-committed to immune regulation within the CD4 + CD25 ± subset (30) .
In sum, we report that in nasal tolerance, T r cells are operating that transfer their tolerogenic potencies to naive T cells. Moreover, we identi®ed a CD4 + CD25 ± T r subset that is antigen speci®c, but exerts its suppressive function regardless of initial or ongoing cytokine polarization.
